EIF3LP3: A Potential Drug Target and Biomarker (G340947)

Target Name: EIF3LP3

NCBI ID: G340947

EIF3LP3

Other Name(s): eukaryotic translation initiation factor 3 subunit L pseudogene 3 | Eukaryotic translation initiation factor 3, subunit L pseudogene 3

EIF3LP3: A Potential Drug Target and Biomarker

Eukaryotic translation initiation factor 3 (EIF3) is a protein that plays a crucial role in the initiation of protein translation in eukaryotic cells. The protein encoded by the EIF3 gene is composed of multiple subunits, including the EIF3 subunit L pseudogene 3 (EIF3LP3). EIF3LP3 is a pseudogene, which means that it is a non-coding gene that has been shown to encode a protein.

Recent studies have identified EIF3LP3 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. In this article, we will discuss the recent findings on EIF3LP3 and its potential as a drug target and biomarker.

Potential Drug Target

EIF3LP3 has been identified as a potential drug target due to its involvement in various cellular processes that are associated with the development and progression of various diseases. EIF3 is a key factor in the initiation of protein translation, which is the process by which proteins are synthesized from mRNA. Therefore, alterations in the translation process can lead to changes in cellular behavior and contribute to the development of diseases.

Studies have shown that EIF3LP3 is involved in various cellular processes that are associated with the development of cancer, neurodegenerative diseases, and autoimmune diseases. For example, EIF3LP3 has been shown to be involved in the regulation of cell adhesion, which is a process that is critical for the maintenance of tissue structure and function. Additionally, EIF3LP3 has been shown to be involved in the regulation of the cytoskeleton, which is a structure that is critical for the proper functioning of cells.

Biomarker

EIF3LP3 has also been identified as a potential biomarker for various diseases. The detection and quantification of EIF3LP3 have been shown to be useful for the diagnosis and monitoring of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

For example, studies have shown that EIF3LP3 levels are significantly increased in various types of cancer, including breast, lung, and ovarian cancer. Additionally, EIF3LP3 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, EIF3LP3 is a pseudogene that has been shown to encode a protein that plays a crucial role in the initiation of protein translation in eukaryotic cells. The recent studies have identified EIF3LP3 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further studies are needed to confirm its potential as a drug and to develop new diagnostic tests for EIF3LP3.

Protein Name: Eukaryotic Translation Initiation Factor 3 Subunit L Pseudogene 3

The "EIF3LP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF3LP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets